The median survival time for clear cell carcinoma patients with nuclear THRα2 expression is only 1.65 years in contrast to 5.24 years for patients with no nuclear THRα2 expression (Fig. 2f, p = 0.034). Here, THRA is linked to clear cell adenocarcinoma.